DGAP-News

Press Release: 4SC's associated company Panoptes Pharma concludes license agreement with Mediolanum for compound PP-001 for inflammatory eye diseases - Seite 2

4SC's own drug discovery platform. We look forward to the further succesful
development of PP-001."

Ends

About Panoptes Pharma and the compound PP-001

Panoptes Pharma is a privately held biotech company, located in Vienna,
Austria and is focused on developing small molecule based therapies for the
treatment of severe eye diseases with high unmet medical need. PP-001 is a
selective anti-inflammatory small molecule compound which has demonstrated
efficacy in preclinical models in ophthalmology. Additionally, PP-001
significantly inhibits abnormal blood vessel growth in the back of the eye
(choroidal neovascularization) in an animal model for autoimmune uveitis.
Inhibition of choroidal neovascularization (CNV) is mediated by the
inhibition of vascular endothelial growth factor (VEGF) by PP-001. CNV is
one of the most severe causes of visual impairment in patients with
posterior uveitis. PP-001 was orginally discovered by 4SC Discovery GmbH
and licensed to Panoptes Pharma in 2013.

About Mediolanum

Mediolanum is a privately owned pharmaceutical Group founded in 1972 by Mr
Rinaldo Del Bono. Its Headquarters are located in Milan, Italy. Core
commercial therapeutic areas are cardiovascular, osteoporosis and diabetes.
From an R&D standpoint, Mediolanum is focusing on innovative treatments
such as cancer vaccines. The Group employs around 450 people with an
aggregated turnover of circa EUR200 million.

About 4SC and 4SC Discovery GmbH

The Group managed by 4SC AG (www.4sc.de) discovers and develops targeted
small-molecule drugs for the treatment of diseases with a high unmet
medical need in various autoimmune and cancer indications. Founded in 1997,
4SC had 66 employees (headcount) or 57 full-time equivalents (FTEs) at 31
December 2014. 4SC AG has been listed on the Prime Standard of the
Frankfurt Stock Exchange since December 2005. 4SC Discovery GmbH
(www.4sc-discovery.com), a wholly-owned subsidiary of 4SC AG, specialises
in early-stage research and discovery of novel therapeutic compounds
against cancer and autoimmune diseases. 4SC Discovery engages in
partnerships with pharmaceutical and biotech companies in order to advance
the development and commercialisation of its own therapeutic programmes. In
addition, as a drug discovery service provider 4SC Discovery offers its
expertise via research collaborations to companies from the pharmaceutical
and biotech industry.

Cautionary statement regarding forward-looking statements
This press release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this press release.